SLC5A2 and diabetes mellitus: SGLT2 inhibitors, such as dapagliflozin, ertugliflozin, empagliflozin, and canagliflozin, have been approved by the FDA for use as a treatment for diabetes since 2013, which works by preventing the kidneys from reabsorbing glucose back into the blood.